91.82
Amedisys Inc. stock is currently priced at $91.82, with a 24-hour trading volume of 251.54K.
It has seen a +0.15% increased in the last 24 hours and a -4.06% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $91.58 pivot point. If it approaches the $91.95 resistance level, significant changes may occur.
Previous Close:
$91.68
Open:
$91.49
24h Volume:
251.54K
Market Cap:
$3.00B
Revenue:
$2.25B
Net Income/Loss:
$-20.59M
P/E Ratio:
1,311.71
EPS:
0.07
Net Cash Flow:
$90.64M
1W Performance:
+0.08%
1M Performance:
-4.06%
6M Performance:
-3.34%
1Y Performance:
+0.51%
Amedisys Inc. Stock (AMED) Company Profile
Name
Amedisys Inc.
Sector
Industry
Phone
225-292-2031
Address
3854 American Way, Suite A, Baton Rouge, LA
Amedisys Inc. Stock (AMED) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-07-23 | Downgrade | Truist | Buy → Hold |
Apr-21-23 | Initiated | Cantor Fitzgerald | Neutral |
Mar-13-23 | Initiated | Barclays | Equal Weight |
Oct-27-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
Aug-02-22 | Downgrade | UBS | Neutral → Sell |
Jun-29-22 | Initiated | Stifel | Hold |
Jun-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
Mar-01-22 | Upgrade | UBS | Sell → Neutral |
Feb-25-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Feb-25-22 | Reiterated | Credit Suisse | Outperform |
Feb-25-22 | Reiterated | Oppenheimer | Outperform |
Feb-25-22 | Reiterated | RBC Capital Mkts | Outperform |
Feb-25-22 | Reiterated | Raymond James | Outperform |
Feb-25-22 | Reiterated | Truist | Buy |
Sep-27-21 | Initiated | SVB Leerink | Mkt Perform |
Sep-24-21 | Initiated | UBS | Sell |
Sep-10-21 | Initiated | Cowen | Market Perform |
Aug-10-21 | Reiterated | The Benchmark Company | Buy |
Aug-05-21 | Downgrade | BofA Securities | Buy → Neutral |
Aug-20-20 | Resumed | Barclays | Overweight |
Jul-30-20 | Reiterated | The Benchmark Company | Buy |
Jun-18-20 | Upgrade | The Benchmark Company | Hold → Buy |
May-07-20 | Downgrade | The Benchmark Company | Buy → Hold |
Mar-09-20 | Upgrade | The Benchmark Company | Hold → Buy |
Jan-17-20 | Initiated | Credit Suisse | Outperform |
Nov-01-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
Oct-22-19 | Resumed | Stephens | Equal-Weight |
Sep-17-19 | Initiated | Deutsche Bank | Buy |
May-02-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
Dec-14-18 | Initiated | Barclays | Equal Weight |
Nov-16-18 | Initiated | UBS | Neutral |
Oct-30-18 | Upgrade | The Benchmark Company | Hold → Buy |
Jul-03-18 | Upgrade | BofA/Merrill | Neutral → Buy |
Mar-19-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Nov-09-17 | Reiterated | RBC Capital Mkts | Sector Perform |
Nov-09-17 | Downgrade | The Benchmark Company | Buy → Hold |
Nov-08-17 | Reiterated | Mizuho | Buy |
Nov-02-17 | Upgrade | The Benchmark Company | Hold → Buy |
Aug-21-17 | Initiated | BofA/Merrill | Neutral |
View All
Amedisys Inc. Stock (AMED) Latest News
Nomura Holdings Inc. Boosts Stake in Amedisys, Inc. (NASDAQ:AMED) - MarketBeat
MarketBeat
Nomura Holdings Inc. Boosts Stake in Amedisys, Inc. (NASDAQ:AMED) - Defense World
Defense World
Angelo Gordon & CO. L.P. Buys Shares of 26057 Amedisys, Inc. (NASDAQ:AMED) - MarketBeat
MarketBeat
Amedisys, Inc. (NASDAQ:AMED) is Water Island Capital LLC's 4th Largest Position - MarketBeat
MarketBeat
Amedisys shares could have downside to $74 a share in a no-deal scenario - analyst - Seeking Alpha
Seeking Alpha
Bardin Hill Management Partners LP Purchases 13,217 Shares of Amedisys, Inc. (NASDAQ:AMED) - MarketBeat
MarketBeat
Amedisys Inc. Stock (AMED) Financials Data
Amedisys Inc. (AMED) Revenue 2024
AMED reported a revenue (TTM) of $2.25 billion for the quarter ending March 31, 2024, a +0.76% rise year-over-year.
Amedisys Inc. (AMED) Net Income 2024
AMED net income (TTM) was -$20.59 million for the quarter ending March 31, 2024, a -118.36% decrease year-over-year.
Amedisys Inc. (AMED) Cash Flow 2024
AMED recorded a free cash flow (TTM) of $90.64 million for the quarter ending March 31, 2024, a -11.99% decrease year-over-year.
Amedisys Inc. (AMED) Earnings per Share 2024
AMED earnings per share (TTM) was -$0.64 for the quarter ending March 31, 2024, a -118.60% decline year-over-year.
About Amedisys Inc.
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Cap:
|
Volume (24h):